Experts

Nirupama Sista, PhD

Director, HPTN Leadership and Operations Center

Areas of expertise

  • HIV prevention
  • Drug development
  • Antiretroviral drugs
  • Clinical research

Projects & Resources

Published Research

  • ARV-based HIV prevention for women – where we are in 2014
    Mastro TD, Sista N, Abdool-Karim Q
    Journal of the International AIDS Society. 2014; 17 (suppl 2): 19154

    Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioral, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention, or TasP). This paper reviews the evidence base for PrEP and TasP and describes new products in development and the need to translate research findings into programs with impact at the population level.

Explore More Related to Nirupama Sista, PhD